You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《新股表現》和黃醫藥(00013.HK)暗盤高開22%報49元
根據輝立交易平臺顯示,明天掛牌的和黃醫藥(00013.HK)暗盤高開22%報49元獲承接,最高見51.45元,現造49.7元,較上市價40.1元,高24%,成交43萬股。

長和(00001.HK)旗下和黃醫藥是一家處於商業化階段全球生物醫藥公司,專注於發現、開發及商業化治療癌症及免疫性疾病的靶向療法及免疫療法。除腫瘤及免疫業務外,和黃醫藥其他業務已建立大規模兼有盈利的藥物營銷及分銷能力,主要在內地生產、營銷及分銷處方藥。

是次在港上市合共發售1.04億股,並已引入包括CA Fern Parent、CPP、泛大西洋投資、HBM Healthcare及中金啓融基金等5名基石投資者,合共認購6,321.55萬股;其中12.5%公開發售獲逾4倍超購,認購一手中籤率60%;股份最終定價40.1元(較最高發售價45元低近11%),料集資淨額約39.5億元,主要用作推進賽沃替尼、索凡替尼、HMPL-689及HMPL-523等後期臨牀計劃以進行註冊試驗與潛在提交NDA申請、支持進一步增強集團的商業化、臨牀、監管及生產實力、爲潛在的全球業務發展及策略收購機會提供資金等。上市聯席保薦人分別爲大摩、Jefferies及中金。

和黃醫藥(HCM.US)於納指上市的美國預託證券(每份代表五股)昨晚收市爲每份33.5美元,升2.3%。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account